HDAC Inhibitors for Neurodegenerative Diseases

HDAC Inhibitors for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">HDAC Inhibitors for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Epigenetic Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Histone Deacetylases (HDACs)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical to Phase II</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Ricolinostat (ACY-1215)</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Vorinostat</td>
<td>Alzheimer's Disease</td>
</tr>
</table>

Hdac Inhibitors For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

HDAC Inhibitors for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">HDAC Inhibitors for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Epigenetic Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Histone Deacetylases (HDACs)</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Preclinical to Phase II</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Ricolinostat (ACY-1215)</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Valproic Acid</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Vorinostat</td>
<td>Alzheimer's Disease</td>
</tr>
</table>

Hdac Inhibitors For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Histone deacetylase (HDAC) inhibitors are a class of drugs that block the activity of histone deacetylases, enzymes that remove acetyl groups from histone proteins. By inhibiting HDACs, these agents increase histone acetylation, promoting a more open chromatin state and facilitating gene expression. In neurodegenerative diseases, [HDAC](/entities/hdac-enzymes) inhibitors have shown promise in reducing pathology and improving cognitive and motor function in preclinical models. [@inhibition2018]

Mechanism of Action

HDAC inhibitors work through several mechanisms relevant to neurodegeneration:

HDAC Classes and Drug Candidates

Class I HDACs (HDAC1, 2, 3, 8)

• Vorinostat (SAHA): FDA-approved for cutaneous T-cell lymphoma; shown to reduce [Aβ](/proteins/amyloid-beta) toxicity in AD models
• Romidepsin (FK228): Potent Class I inhibitor; preclinical studies in PD models
• Valproic Acid: Used for epilepsy/bipolar disorder; has HDAC inhibitory activity; mixed clinical results in AD

Class IIa HDACs (HDAC4, 5, 7, 9)

• Trichostatin A: Experimental compound; neuroprotective in HD models
• Scriptaid: Experimental HDAC inhibitor; improves learning in AD models

Class IIb HDACs (HDAC6, 10)

• Tubastatin A: Selective HDAC6 inhibitor; promotes α-syn and tau clearance via autophagy
• ACY-1215 (Ricolinostat): HDAC6 inhibitor in clinical trials for ALS
• Citarinostat (ACY-241): Selective HDAC6 inhibitor; cognitive benefits in AD models

Class III HDACs (Sirtuins)

• SRT2104: SIRT1 activator; in development for neurodegeneration
• SRT3025: SIRT1 activator; improves cognition in AD models

Disease-Specific Applications

Alzheimer's Disease

• HDAC2 is elevated in AD brain and correlates with memory deficits
• HDAC inhibitors reverse memory deficits in AD mouse models
• Class I and IIa HDAC inhibitors show most promise
• Current focus on selective HDAC6 inhibitors with better brain penetration

Parkinson's Disease

• HDAC inhibitors protect dopaminergic [neurons](/entities/neurons) from α-syn toxicity
• HDAC6 inhibitors promote clearance of Lewy body proteins
• Valproic acid and vorinostat have shown neuroprotective effects

Huntington's Disease

• HDAC inhibitors reduce mutant [huntingtin](/proteins/huntingtin-protein) aggregation
• Improve motor function and survival in HD mouse models
• Vorinostat and sodium butyrate have been studied

ALS

• HDAC inhibitors may benefit SOD1 and [TDP-43](/proteins/tdp-43) models
• ACY-1215 (ricolinostat) in clinical trials for ALS
• Focus on HDAC6 selective inhibition to avoid Class I side effects

Clinical Trials

Adverse Effects

Common side effects include:

• Fatigue, nausea, diarrhea
• Thrombocytopenia (platelet decrease)
• Weight loss
• Class I inhibitors: more systemic toxicity
• HDAC6 selective inhibitors: improved tolerability

Research Directions

See Also

• [Epigenetics in Neurodegeneration](/epigenetics-in-neurodegeneration)
• [Histone Modifications](/histone-modifications)
• [Sirtuins in Aging and Neurodegeneration](/mechanisms/sirtuin-pathway)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)

External Links

• [HDAC Inhibitors - Nature Reviews Drug Discovery](https://www.nature.com/nrd/)
• [Epigenetic Therapy Research - NIH](https://www.nih.gov/)
• [ClinicalTrials.gov - HDAC Inhibitors](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=HDAC)
• [Alzheimer's Association](https://www.alz.org/)
• [Cochrane Review - HDAC Inhibitors](https://www.cochranelibrary.com/)

Background

The study of Hdac Inhibitors For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;